AzTrials
AzTrials

Pre DiabetesMG3NCT06986161

Optimizing Mango's Glycemic Impact: Investigating Mango Consumption Timing in Prediabetic Individuals

A study testing Mango in people with Pre Diabetes, run by Clinical Nutrition Research Center, Illinois Institute of Technology at 1 site in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The purpose of this study is to investigate the effect of mango intake on metabolic and inflammatory responses relative to meals in individuals at risk of developing diabetes, as well as to understand how the beneficial compounds found in mangoes are absorbed and processed in the body. Read more about this study

Who is it for?
Ages 20 to 60 yearsHealthy volunteers can take part
Conditions the study is for
Pre Diabetes
What is being tested?
Mango
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
33 participants
Where
1 siteUnited States
Study dates
14 Apr 2025to 31 Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Be between 20-60 years old.
  • Have a BMI of 25-35 kilograms per square meter.
  • Have fasting blood glucose between 100-125 milligrams per deciliter or Glycated hemoglobin (HbA1c) between 5.7-6.4%.
  • Be non-smokers for at least 12 months.
  • Be generally healthy, with no major organ-related diseases.
  • Not take medications or supplements that could interfere with the study.
  • Be able to follow study procedures, including dietary restrictions and scheduled visits.

Who cannot join

  • Smoke, vape, or use marijuana.
  • Have allergies or intolerance to mangoes or study foods.
  • Have blood pressure above 160/100 millimeters of Mercury.
  • Have fasting blood glucose above 125 milligrams per deciliter.
  • Have a history of major heart disease, stroke, or cancer in the past five years.
  • Be pregnant, planning to become pregnant, or breastfeeding.
Show all 16Show fewer
  • Take anti-inflammatory drugs or certain dietary supplements.
  • Have had major surgery or trauma in the past two months.
  • Follow extreme diets (e.g., vegan, Atkins).
  • Have used antibiotics in the last six weeks.
  • Have a history of eating disorders or substance abuse in the past two years.
  • Drink more than three cups of coffee or tea per day.
  • Have donated blood in the last three months.
  • Be professional athletes or do excessive exercise.
  • Have had weight changes of more than 11 pounds in the past two months.
  • Work overnight shifts.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Clinical Nutrition Research Center

    Chicago, Illinois, 60616

Other trials in United States

About this study

Official title: Optimizing Mango's Glycemic Impact: Investigating Mango Consumption Timing in Relation to Meal in Prediabetic Individuals

The purpose of this study is to investigate the effect of mango intake on metabolic and inflammatory responses relative to meals in individuals at risk of developing diabetes, as well as to understand how the beneficial compounds found in mangoes are absorbed and processed in the body.

Read the detailed description

The primary goal of the proposed project is to advance current knowledge about the antidiabetic and anti-inflammatory benefits of consuming mangoes, especially in individuals with prediabetes, and to determine the best timing of mango intake relative to meals.

Participation in this study will last approximately five weeks and will include six visits: one screening visit lasting about one hour and four study-day visits, each lasting approximately eight hours. During these study visits, blood and urine samples will be collected to help researchers better understand the effects of mango intake relative to meal consumption.

Screening Visit:

Participant eligibility for the study is based on the inclusion and exclusion criteria. To assess this, the participant will need to arrive at the Clinical Nutrition Research Center (CNRC) fasting for 10-12 hours, meaning no food or drink other than plain water during this period.

During the screening visit, the following assessments will be conducted:

  • The participant will complete a screening questionnaire about their health, dietary habits, and physical activity history.
  • The participant's height, weight, waist circumference, and body composition will be measured. Their Body Mass Index (BMI) will be calculated based on their height and weight. BMI is an estimate of body fat that applies to both adult men and women.
  • The participant's forehead temperature, blood pressure, and heart rate will be measured. They will be seated in a comfortable chair with their feet flat on the ground and uncrossed. They will be asked to relax for five minutes before their blood pressure and heart rate are recorded.
  • A finger prick test will be performed to check their blood sugar levels.
  • A licensed healthcare practitioner (LHCP) and/or a certified phlebotomist will assess their arm veins using a vein access scale test. A butterfly needle will then be used to draw 3 milliliters (mL) of blood from their arm to measure their plasma blood glucose levels.
  • If the participant is a woman under the age of 60 year, they will be required to take a pregnancy test.

Based on the results of the questionnaire, blood glucose levels, physical measurements, and overall health evaluation, the participant may meet the eligibility criteria and be invited to participate in the study. If eligible, they will also be instructed to complete a 24-hour food recall, documenting their food intake over the past day.

PRE-STUDY VISIT: (which may take place on the same day as the screening visit or on a different day)

If the participant qualifies based on their screening results, the Pre-Study visit can take place immediately after their screening or on a later date. This visit lasts approximately 30-45 minutes, during which they will meet with one of our investigators who will provide detailed instructions on the study procedures and how to prepare for each study day. They will also receive training on study procedures, including dietary restrictions, medications and supplements to avoid, food and gastrointestinal assessment (GI-tract diary recording), and overnight fasting requirements. Their study dates will be scheduled, and they will receive a study booklet containing their study calendar and all the instructions covered during the Pre-Study visit.

Procedures for Each Study Day Visit (Visits 1, 2, 3, and 4)

Participants will visit the Clinical Nutrition Research Center (CNRC) on four separate occasions, with a seven-day washout period between each visit. They will consume either the equivalent of one cup of fresh mango (165 grams, ~100 kilocalories) or a calorie-matched control beverage (230 grams, ~100 kilocalories) before, with, or after a meal, as outlined in the study schema.

Confirmation that the participant is prepared for a study day visit: We will collect their three-day food record and verify that they have fasted overnight, consumed a standardized dinner meal, avoided the specified food items, had sufficient sleep, and maintained dietary and exercise patterns consistent with the study procedures. Once everything is confirmed, they will proceed to an exam room, where we will measure their weight, body composition, vital signs (blood pressure, heart rate, and forehead temperature), and check their fasting blood glucose with a finger prick test.

Urine collection: The participant will collect a urine sample using a urine collection cup at the start of the visit (0 hours). Additional samples will be collected at 1 hour, 2 hours, 3 hours, 5 hours, and 7 hours, for a total of six collections throughout the visit.

Blood collection: The Licensed Health Care Provider (LHCP) will collect their blood samples. They can choose between an intravenous catheter or multiple butterfly sticks. A total of seven blood draws will be taken at 0 hours, 0.5 hours, 1 hour, 2 hours, 3 hours, 5 hours, and 7 hours.

Study Beverages and Standardized Breakfast: Once the fasting blood and urine samples are collected, they will receive a pre-meal study beverage. After the 1-hour blood draw, they will be provided with a standardized breakfast meal and a study beverage. Following the 2-hour blood draw, they will receive a post-meal study beverage.

ASA24 Food Recall: The Online Dietary Questionnaire (ASA24) is a web-based questionnaire. We will ask the participant to report everything they ate and drank over the previous day. This questionnaire may take up to 45 minutes to complete each time.

At the End of the Study Day: The participant will be evaluated for safety and any discomfort or symptoms before leaving. They will receive a take-home snack, and compensation will be issued after all study procedures are completed. Additionally, they will be given instructions on how to prepare for their next visit.

How much blood will be collected during the study visit?: During each of the four study visits, blood will be collected a total of seven times per visit, with a total of 280 milliliters of blood collected throughout the study across all visits.

Conditions
Pre Diabetes
Being tested
Mango, Control Beverage
Medical subject headings
Glucose Intolerance

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MangoOther

    Mango beverage

  • Control BeverageOther

    Italian Ice beverage

Study groups in NCT06986161
Study groupRoleWhat they receive
Mango Before MealExperimental1 cup (165 grams) of mango before standardized breakfast
Receives: Other: Mango
Mango With MealExperimental1 cup (165 grams) of mango with standardized breakfast
Receives: Other: Mango
Mango After MealExperimental1 cup (165 grams) of mango after standardized breakfast
Receives: Other: Mango
Control (no mango)Placebo comparatorControl beverage (230 grams) with standardized breakfast
Receives: Other: Control Beverage

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in postprandial glucose

    Change in postprandial glucose as measured by absolute values and calculated insulin sensitivity using homeostasis model assessment of fasting insulin sensitivity (HOMA-%S) and B-cell function (HOMA-%).

    Measured: 7 hours

  2. Change in postprandial glucose through peripheral insulin sensitivity

    Change in postprandial glucose as measured by assessment of peripheral insulin sensitivity using Matsuda index.

    Measured: 7 hours

  3. Change in postprandial insulin

    Change in postprandial insulin as measured by absolute values and calculated insulin sensitivity using homeostasis model assessment of fasting insulin sensitivity (HOMA-%S) and B-cell function (HOMA-%).

    Measured: 7 hours

  4. Change in postprandial insulin through peripheral insulin sensitivity

    Change in postprandial insulin as measured by assessment of peripheral insulin sensitivity using Matsuda index.

    Measured: 7 hours

  5. Evaluate Interleukin-6 (IL-6) as an index of systemic inflammatory response

    Assessments to address this aim will include analysis of systemic markers of inflammation (IL-6) in plasma using ELISA method

    Measured: 7 hours

  6. Evaluate Tumor Necrosis Factor-alpha (TNF-α) as an index of systemic inflammatory response

    Assessments to address this aim will include analysis of systemic markers of inflammation (TNF-α) in plasma using ELISA method

    Measured: 7 hours

Secondary outcomes (1)
  1. Characterize metabolite profiles

    Polyphenolic metabolites (phenolic acids and derivatives components) will be identified and quantified in urine and plasma. Metabolites in samples will be identified and quantified using an Agilent 6550 iFunnel ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC/Q-TOF-MS) and 6460 ultra-high performance liquid chromatography- triple quadrupole mass spectrometry (UHPLC-QQQ-MS), respectively

    Measured: 7 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 May 2025
  2. Study start14 Apr 2025
  3. Primary completion6 Jul 2026
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Model description
The pilot study will use a single-blinded, randomized, 4-arm, within-subjects crossover design lasting approximately 5 weeks.
Masking
Single blind
Who is masked
Participant
Enrolment
33 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06986161
Sponsor's protocol ID
2025-95
Acronym
MG3
Status last verified
Aug 2026
First submitted
7 May 2025
Last updated
28 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Mango in people with Pre Diabetes, run by Clinical Nutrition Research Center, Illinois Institute of Technology at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 28 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in postprandial glucose (time frame: 7 hours). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in